07 jun: USA/tendens: Kina og Spanien ventes at give stigninger
07 jun: Carlsberg: Ølsalget firedobles før EM-kamp
07-06-2012 14:57:00

PRESS RELEASE: Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions

Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions

Powerful New Certegra(R) Informatics Workstation launched at SIIM 2012

Intended for U.S. Media Only

PR Newswire

TARRYTOWN, N.Y., June 7, 2012

TARRYTOWN, N.Y., June 7, 2012 /PRNewswire/ -- Bayer Radiology & Interventional announced the introduction of the Certegra(R) Workstation, an informatics-driven, touch--screen hub that enables time savings and improved patient care through a powerful suite of CT Contrast Dose Management(TM) applications and a new P3T(R) 2.0 operating environment. The new Workstation will be presented at the annual meeting of the Society for Imaging Informatics in Medicine (SIIM) 2012 June 7 - 12 in Orlando, FL. Following the initial launch in the U.S. and Canada, the Workstation will be rolled out in phases in markets around the world.

The Workstation serves as a single interface for radiology technologists, enabling them to provide improved patient care from study set-up and preparation to administration of the patient's study. It will be the cornerstone of Bayer's industry-first[1] Contrast Dose Management solution and informatics platform. In establishing and uploading the patient's contrast-injection record, the Workstation imports patient data directly from the Modality Work List -- reducing manual entry errors to the patient record.

"Today's technology-driven CT suite demands timely access to reliable contrast-dose records throughout the chain of care," said Anthony Cinalli, vice president of the informatics business at Bayer Radiology & Interventional. "Enabling a single workflow-centralized interface, the Workstation allows for fewer clicks, less manual entry and greater control over the quality and consistency of patient care."

Interfacing with Medrad Stellant(R) CT injection systems, the Workstation's comprehensive suite of software options provides physicians and healthcare professionals instant access to real-time actionable CT contrast data captured at the point of care enabling benefits including:

-- Reduce sub-diagnostic studies, unnecessary rescans and associated

radiation exposure[2] [3],(P3T 2.0 for personalized CT abdominal, cardiac

and pulmonary angiography studies)

-- Enable more complete diagnostic decisions (PACS Outbound Interface)

-- Speed-up radiology report turnaround time and create greater study-volume

bandwidth (RIS and SR Outbound Interfaces)

-- Improve department performance by trending, reporting and analyzing

actionable data with pinpoint accuracy (Informatics Starter Package, and

the Data Analysis and Reporting Tool)

Bayer HealthCare will have the Certegra(R) Workstation on display at its booth at SIIM 2012 (booth #217 - 221).

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

[1] Reference on file.

[2] Presented at Society of Thoracic Radiology (2008) Poster Session; Christopher R. Deible, MD, PhD. Study supported by MEDRAD Inc.

[3] 510(k) FDA clearance number: K082905

SOURCE Bayer HealthCare

/CONTACT: Karen Sutherland, +1-973-487-2113, karen.sutherland@bayer.com or Alicia Cafardi, +1-724-940-8621, alicia.cafardi@bayer.com

/Web site: http://www.bayerhealthcare.com/

(END) Dow Jones Newswires

June 07, 2012 08:57 ET (12:57 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
27 aug
I:SP500
Indlægget her er kraftigt inspireret af overlaar@ (filter) og alpe med flere, kort og godt alle dem ..
46
29 aug
 
Har man en halv times tid denne weekend kan den med fordel bruges på to ting: Dels på investeringsdi..
28
26 aug
RTX
Investor 1989, - nej tak, - jeg er ikke interesseret i at give 15 dollars for en analyse fra dig omk..
28
27 aug
 
2.000.000 til 5.000.000 kr.
21
26 aug
VWS
Det er dog noget af det skægeste jeg længe har læst. Vindmøllegiganten Vestas er et af en stribe dan..
21
30 aug
OMXC20
20
28 aug
OMXC20CAP
Så sluttede fredagen og igen tog jeg fejl.I tirsdags var jeg helt sikker på at frygten ville tage ti..
20
27 aug
 
fra 1.000.000 til 2.000.000 kr.
19
27 aug
 
fra 100.000 til 250.000 kr.
17
27 aug
OMXC20
  Kære alle. Den seneste uge må have fået alles øjne op for hvor umuligt det er at forudsige den kor..
16

Finansiel uro udløste intens børshandel i august

01-09-2015 15:29:44
Omsætningen på Nasdaq-børserne i Norden og i de baltiske lande steg markant i august - i takt med at volatiliteten på de finansielle markeder voksede.Det oplyse..

Lilly får generelt tilskud til nyt insulin i Danmark

01-09-2015 12:20:52
Novo Nordisks amerikanske konkurrent, Eli Lilly, har fået generelt tilskud i Danmark til sit nye langtidsvirkende insulin Abasaglar. Det fremgår af en meddelels..

Aktier/middag: Samtlige C20-aktier i rødt

01-09-2015 11:41:47
Det danske aktiemarked ligger tirsdag middag til et større fald, ligesom det i øvrigt er tilfældet for de øvrige markeder i Europa. Allerede fra dagens begyndel..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab/Nordea. Kurstrigger rykker tætter på
2
Aktier/tendens: Lille comeback i vente til aktierne
3
HOLLANDSK MÆGLER: UDVIKLINGEN ER GÅET HURTIGERE EN
4
Genmab/Jefferies: Løfter kursmål med 25 pct.
5
Tirsdagens aktier: Bred nedtur anført af TDC, Genmab og Novo

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
2. september 2015 12:34:50
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150824.1 - EUROWEB7 - 2015-09-02 12:34:50 - 2015-09-02 12:34:50 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x